On October 25, 2023, the Board of Directors of MIRA Pharmaceuticals, Inc. unanimously approved the election and appointment of Mr. Brian Daly to the Board. Mr. Daly was concurrently appointed as the Chairperson for the Audit Committee of the Board and as a member of the Compensation Committee of the Board. Mr. Daly currently serves as Managing Partner at Dalglish Investment Holdings, LLC, an advisor and provider of seed capital to startup companies.

Before establishing Dalglish, Mr. Daly worked on Wall Street for over 30 years. He began his career with Smith Barney H.U. in 1985, before joining the Asset management Group at Solomon Brothers in 1988. In 1994, he became a member of the Investment Banking Division of Paine Webber with a focus on Convertible Structured Products.

He joined Omicron Capital, a private Equity Fund, in 1997 as the CFO. In 2006, Mr. Daly was a founding partner of Rockmore Capital, where he served as the CFO and member of the Investment Committee. Mr. Daly is a graduate of Fordham University and received his MBA from Columbia University.

Also, on October 19, 2023, David Vorhoff, resigned from the Board of Directors of the Company. At the time of Mr. Vorhoff?s resignation, Mr. Vorhoff served as the Chairperson of the Audit Committee, and a member of the Compensation Committee. Mr. Vorhoff?s decision to resign did not involve disagreements with the Company, the Company?s management, or the Board of Directors on any matter relating to the Company?s operations, policies, or practices.